6-KThe Wire
Sanofi files 6-K
Filed Jun 24, 2026 · 9d ago · Accession 0001193125-26-280319
Plain English
Sanofi announced the approval of its Sarclisa subcutaneous formulation in Japan for multiple myeloma patients and its Cenrifki (tolebrutinib) in the EU for secondary progressive multiple sclerosis. The company also announced the approval of Wayrilz in Japan for immune thrombocytopenia and the appointment of Paulo Fontoura as Global Head of R&D.
Filing details
- Company
- Sanofi
- Ticker
- SNY
- CIK
- 1121404
- Form type
- 6-K
- Filing date
- Jun 24, 2026
- Report date
- Jun 24, 2026
- Document
- d118903d6k.htm
- Size
- 116 KB